(Atlanta, December 10, 2017) — Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies. Most standard chemotherapy drugs work by killing cells in the body that are growing and dividing rapidly; this includes cancer cells, but the drugs don’t distinguish between cancer cells and normal cells. Targeted drugs, by contrast, are designed to zero in on and neutralize genetic features of cancer cells that make them different from normal cells and allow the cancer cells to grow and spread. Because they are designed to specifically target cancer cells while leaving normal cells alone, targeted therapies usually have different, and sometimes milder, adverse side effects than standard chemotherapy drugs. “These studies illustrate how better scientific understanding of what drives cancer at the molecular level is leading to novel therapies capable of keeping patients’ cancers in check for extended periods of time, while also helping them achieve better quality of life,” said press briefing moderator Laurie Sehn, MD, medical oncologist at the… Read full this story
- New Cancer Therapy Can 'Overcome Cancer's Natural Resistance Mechanisms' – Prof
- A&E four-hour target in doubt as new health secretary Matt Hancock promises to listen to NHS leaders
- NHS cuts and performance targets are 'beyond reach', health service leaders warn
- Kane challenges England to target European glory in two years’ time
- Statins found to enhance efficacy of chemotherapy drug in blood cancers
- Russian Researcher Discusses Role of Biomarkers in Treating Cancer
- Largest grant ever to research autism awarded by Innovative Medicines Initiative; Trinity College to take part in trials
- Gran says cannabis oil has blasted 33mm tumour
- Paramedics given power to issue prescriptions amid growing pressures on GP services
- What is prostate cancer and what are the red-flag signs and symptoms all men need to know?
Targeted therapies show promise improving outcomes across several hematologic malignancies have 320 words, post on www.eurekalert.org at December 10, 2017. This is cached page on VietMaz. If you want remove this page, please contact us.